基于均匀设计的泽泻体外抗草酸钙结晶的有效组分配伍研究  

Research on effective components compatibility of Alismatis Rhizoma resisting calcium oxalate calculus in vitro based on uniform design

作　　者：黄锦芳[1] 李小艳[1] 黄小强[1] 吴婷婷[1] 许文[1,2] 吴水生[1] 

机构地区：[1]福建中医药大学药学院,福建福州350122 [2]福建中医药大学生物医药研发中心,福建福州350122

出　　处：《中草药》2016年第23期4160-4165,共6页Chinese Traditional and Herbal Drugs

基　　金：国家自然科学基金资助项目(U1205022);福建省教育厅A类科技课题(JA15242);福建中医药大学校管课题(X2014107-学科;X2015011-平台);福建省大学生创新创业训练计划项目(201610393059)

摘　　要：目的研究泽泻中6种主要三萜成分(泽泻醇A、24-乙酰泽泻醇A、泽泻醇B、23-乙酰泽泻醇B、泽泻醇F和24-乙酰泽泻醇F)及其组分配伍对体外抗草酸钙结石的作用。方法采用均匀设计法设计不同泽泻三萜组分配伍组,应用标准钙离子种晶技术分别检测不同配伍组对草酸钙结晶生长的抑制指数。结果 6种成分及其不同比例配伍组溶液均能抑制草酸钙晶体生长(P<0.05),其中泽泻醇A-24-乙酰泽泻醇A-泽泻醇B-23-乙酰泽泻醇B-泽泻醇F-24-乙酰泽泻醇F(2.2∶3.8∶1∶3.5∶2.2∶1)组分配伍时体外抑制草酸钙结石效果最佳(P<0.05),抑制指数为188.29%。结论泽泻三萜成分是泽泻抑制草酸钙结晶的重要药效物质基础,泽泻醇A、24-乙酰泽泻醇A、泽泻醇B、23-乙酰泽泻醇B、泽泻醇F和24-乙酰泽泻醇F均具有体外抑制草酸钙结石生长的作用,且6种成分合用作用更强,其最佳组分配比为泽泻醇A-24-乙酰泽泻醇A-泽泻醇B-23-乙酰泽泻醇B-泽泻醇F-24-乙酰泽泻醇F(2.2∶3.8∶1∶3.5∶2.2∶1)。Objective To investigate the inhibitory effect of six active triterenoids and their compatibility from Alisma orientale on the formation of urinary calcium oxalate calculus in vitro.Methods A uniform design method was used to design the different compatibilities from six triterenoids.The inhibitory effects of the six triterenoids along with their different compatibility groups were evaluated in vitro using a standard seeded crystallization technique.Results The six active triterenoids and their compatible preparations could significantly inhibit calcium oxalate crystal formation in vitro （P〈0.05）,and the group of alisol A-alisol A 24-acetate-alisol B-alisol B 23-acetate-alisol F-alisol F 24-acetate （2.2：3.8：1：3.5：2.2：1） was the most efficient with an inhibitory index of 188.29%.Conclusion The triterenoids in A.orientale play a key role in the inhibition of calcium oxalate calculus formation and compatibility of alisol A,alisol A 24-acetate,alisol B,alisol B 23-acetate,alisol F,and alisol F 24-acetate can inhibit the calcium oxalate calculus well in vitro especially cooperated with each other,and the best compatibility proportion is 2.2：3.8：1：3.5：2.2：1,respectively.

关 键 词：泽泻 三萜 配伍 草酸钙结晶 结石 均匀设计 组分配伍 泽泻醇A 24.乙酰泽泻醇A 泽泻醇B 23.乙酰泽泻醇B 泽泻醇F 24-乙酰泽泻醇F 抑制指数 

分 类 号：R283.1[医药卫生—中药学]